crore from Rs.60.27 crore Its net sales remained flat at Rs.704 crore as against Rs.706 crore. In the last period GSK has shown Rs.17.89 crore as exceptional income. EPS improved to Rs.10.6 as compared to Rs.6.3 in the last period.
Commenting on the results, A. Vaidheesh, managing director, said, “Overall underlying performance, excluding the impacts of GST and prior year disposals, is supported by high single to double digit volume growth on our key brands and therapy areas. An improved product mix, other credits to consumption, lower stock impairments combined with optimisation of costs contributed to an EBITDA margin of 21% in the quarter.
During the quarter the company has received the money in advance towards disposal of Thane land. The transfer of the said land will happen upon obtaining all relevant statutory and other permissions. The amount received has been accounted as advance against sale of land.”
For the nine months period, GSK's net sales declined by 2.9 per cent to Rs.2,147 crore from Rs.2,211 crore in the similar period of last year. Its net profit moved up by 10 per cent to Rs.246 crore from Rs.224 crore.